Interdisciplinary approach to the management of patients with perforating dermatosis (clinical case)
DOI:
https://doi.org/10.14739/2310-1237.2025.2.334422Keywords:
acquired perforating dermatosi, multimorbidity, histological examination, treatmentAbstract
The aim of this work is to describe a clinical case of acquired perforating dermatosis within the context of an interdisciplinary approach to patient management, taking into account a comprehensive therapeutic and dermatological diagnostic and therapeutic algorithm.
Materials and methods. A personal observation is described of a 70-year-old patient with clinical manifestations of acquired perforating dermatosis and multimorbid somatic pathology, the verification of which was carried out taking into account the results of laboratory and instrumental diagnostic methods. The dermatological diagnosis was established based on the morphological assessment of a skin biopsy.
Results. A clinical case of a patient with skin lesions of the trunk and upper extremities is described. Visual manifestations of dermatosis are represented by a papular rash with a central depression, erosions, hyperkeratotic changes, and pronounced itching, which in general mimic a wide range of nosologies: from lichen planus, prurigo to multiple keratoacanthomas. Given such clinical non-specificity of the pathological process on the skin, only morphological diagnostics can contribute to the final verification of the dermatological diagnosis. In addition, an important aspect was the assessment of the patient’s somatic status, which revealed the presence of multimorbidity, in particular concomitant cardiovascular pathology, chronic kidney disease, cryptogenic liver cirrhosis, and portal hypertension. The general therapeutic direction of this disease is to compensate for the underlying somatic pathology. That is why, given the clinical complexity of the condition, patients in this category require the mandatory involvement of physicians from related specialties. In this case, the patient requires constant therapeutic support, including in the conditions of an inpatient ward. Given the severe general status of the patient, it was decided, in parallel with the treatment of somatic pathology, to have a rather gentle effect on the efflorescence, only with the use of systemic antihistamines and topical therapy with glucocorticosteroids. The positive dynamics within the skin justify the expediency of continuing the planned comprehensive therapeutic tactics.
Conclusions. Morphological examination is the gold standard for verifying pathological processes in the skin. Considering the rather variable nosologies in the context of multimorbidity in one patient, as well as the clear dependence of the course of dermatosis on somatic pathology, a mandatory stage in the management of such patients is the joint interdisciplinary work of specialists of both dermatological and therapeutic profiles.
References
Harbaoui S, Litaiem N. Acquired Perforating Dermatosis. [Updated 2023 Feb 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539715/
Roldan-Contreras SE, Mendoza Martínez JR, Marin-Hernandez E, Coronado-Malagón M. Acquired Perforating Dermatosis and Dermatology Life Quality Index in Patients Receiving hemodialysis. Nefrologia (Engl Ed). 2024;44(2):251-5. doi: https://doi.org/10.1016/j.nefroe.2024.03.006
Gao Z, Lu SJ, Shan SJ. Acquired perforating dermatosis: A clinicopathologic study, and the features of dermoscopy and reflective confocal microscopy of 37 cases. Skin Res Technol. 2023;29(7):e13416. doi: https://doi.org/10.1111/srt.13416
Mima Y, Ohtsuka T, Ebato I, Nishie R, Uesugi S, Sumi M, et al. A Case of Acquired Reactive Perforating Dermatosis with Complete Resolution of Eruptions on Upper and Lower Limbs During the Treatment of Diabetes Mellitus and Peripheral Artery Disease. Medicina. 2025;61(1):36. doi: https://doi.org/10.3390/medicina61010036
Garrido PM, Queirós C, Borges-Costa J, Soares-Almeida L, Filipe P. Acquired perforating dermatosis: clinicopathologic study of a 10-year period at a tertiary teaching hospital. Int J Dermatol. 2020;59(4):445-50. doi: https://doi.org/10.1111/ijd.14760
Kawakami T, Akiyama M, Ishida-Yamamoto A, Nakano H, Mitoma C, Yoneda K, et al. Clinical practice guide for the treatment of perforating dermatosis. J Dermatol. 2020;47(12):1374-82. doi: https://doi.org/10.1111/1346-8138.15647
García-Malinis AJ, Del Valle Sánchez E, Sánchez-Salas MP, Del Prado E, Coscojuela C, Gilaberte Y. Acquired perforating dermatosis: clinicopathological study of 31 cases, emphasizing pathogenesis and treatment. J Eur Acad Dermatol Venereol. 2017;31(10):1757-63. doi: https://doi.org/10.1111/jdv.14220
Wang MF, Mei XL, Wang L, Lin-Feng L. Clinical characteristics and prognosis of acquired perforating dermatosis: A case report. Exp Ther Med. 2020;19(6):3634-40. doi: https://doi.org/10.3892/etm.2020.8651
Edek YC, Aypek Y, Öğüt B, Erdem Ö, Adışen E. Acquired Perforating Dermatosis: Clinical and Histopathological Analysis of 95 Patients From One Center. Dermatol Pract Concept. 2024;14(2):e2024100. doi: https://doi.org/10.5826/dpc.1402a100
Liu B, Wu Y, Wu X, Zhong X, Xue R, Zhang Z. Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation. Front Immunol. 2023;14:1240262. doi: https://doi.org/10.3389/fimmu.2023.1240262
Metterle L, Magro CM, Zang JB. Giant variant of acquired perforating dermatosis in a renal dialysis patient. JAAD Case Rep. 2017;3(1):42-4. doi: https://doi.org/10.1016/j.jdcr.2016.10.004
Agrawal A, Singal A, Devanda R, Arora VK. Scabies surrepticius masquerading as perforating dermatosis. Indian J Dermatol Venereol Leprol. 2024:1-4. doi: https://doi.org/10.25259/IJDVL_834_2023
Іmran N. Acquired Perforating Dermatosis as a Paraneoplastic Feature: A Case Report, Literature Review, and Novel Association. Case Rep Nephrol Dial. 2023;13(1):36-44. doi: https://doi.org/10.1159/000530756
Wang S, Min X, Wang X, Cheng L, Qiu L. A case of acquired reactive perforating collagenosis after COVID-19 infection. Postepy Dermatol Alergol. 2024;41(5):536-7. doi: https://doi.org/10.5114/ada.2024.142575
Sciamarrelli N, Siliquini N, Mastorino L, Senetta R, Dapavo P, Ribero S, et al. Exacerbation of acquired perforating dermatosis following SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol. 2023;37(9):e1091-3. doi: https://doi.org/10.1111/jdv.19137
Mądrzak L, Staniszewska I, Moskwa A, Kalińska-Bienias A. Drugs as a cause of perforating dermatoses – a literature review. Dermatology Review/Przegląd Dermatologiczny. 2024;111(3):209-21. doi: https://doi.org/10.5114/dr.2024.144652
Fisher RM, Hadley G, Ieremia E, Moswela O, Zaki F, DeLuca GC, et al. Natalizumab-induced acquired perforating dermatosis. Clin Exp Dermatol. 2021;46(7):1373-5. doi: https://doi.org/10.1111/ced.14699
Liu X, Wang H, Wan Y, Guo Y, Shan SJ. Acquired Perforating Dermatosis Induced by PD-1 Inhibitor: A Case Report. Am J Dermatopathol. 2021;43(12):942-4. doi: https://doi.org/10.1097/DAD.0000000000002026
Du XH, Huang SY, Zeng XF, Lu SJ, Gao Z. Acquired Perforating Dermatosis After Herpes Zoster: Wolf Isotopic Response. J Cutan Pathol. 2025;52(1):16-9. doi: https://doi.org/10.1111/cup.14728
Tai A, Prakash S, Lade S, McCormack CJ, Goh MS. Two cases of acquired perforating dermatosis successfully treated with allopurinol. Australas J Dermatol. 2022;63(1):121-4. doi: https://doi.org/10.1111/ajd.13712
Schremser V, Tittes J, Tanew A, Radakovic S. Sustained clearance of acquired perforating dermatosis after narrowband UVB phototherapy: A retrospective cohort study on seven patients. J Eur Acad Dermatol Venereol. 2023;37(6):e747-8. doi: https://doi.org/10.1111/jdv.18904
Kharghoria G, Grover C. Treatment of acquired perforating dermatosis with colchicine. Indian Dermatol Online J. 2022;13(1):131-2. doi: https://doi.org/10.4103/idoj.IDOJ_163_21
Gil F, Cardoso JC, Gil J. Successful Treatment of Acquired Perforating Dermatosis with Colchicine. Indian Dermatol Online J. 2021;12(2):355-6. doi: https://doi.org/10.4103/idoj.IDOJ_504_20
Ye B, Cao Y, Liu Y. Successful treatment of acquired reactive perforating collagenosis with itraconazole. Eur J Med Res. 2021;26(1):74. doi: https://doi.org/10.1186/s40001-021-00542-6
Gori N, De Luca E, Chiricozzi A, Sfregola S, Di Stefani A, Peris K. Successful Use of Dupilumab in the Treatment of Acquired Perforating Dermatosis Associated with Atopic Dermatitis. Case Rep Dermatol Med. 2024;2024:6265608. doi: https://doi.org/10.1155/2024/6265608
Alsebayel MM, Alzaid T, Alobaida SA. Dupilumab in acquired perforating dermatosis: A potential new treatment. JAAD Case Rep. 2022;28:34-36. doi: https://doi.org/10.1016/j.jdcr.2022.08.013
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 V. A. Vizir, H. I. Makurina, O. V. Demidenko, L. O. Horodokina

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.